How GLP-1 Therapies Are Reshaping Pharmaceutical Manufacturing, Drug Delivery, and Supply Chain Economics
Day 2 Packaging & Device Innovation Stage
07/10/2026 11:00 - 11:30am
Contributors
Mike Martin : President & CEO - ISPE
GLP-1 therapies are transforming far more than obesity treatment. They are reshaping manufacturing networks, supply chains, drug delivery technologies, capital investment strategies, and patient expectations. As injectable and oral therapies continue to evolve, pharmaceutical companies face difficult decisions about manufacturing capacity, delivery platform investments, facility design, and long-term supply resilience.
This keynote examines how GLP-1 therapies are redefining the economics of drug delivery from a manufacturing, engineering, and operational perspective, highlighting the strategic choices that will shape the next generation of pharmaceutical production.